Efficacy of Supplementation with Iron Sulfate Compared to Iron Bisglycinate Chelate in Preterm Infants
| Autor: | Elena Spada, E Cester, Paola Saracco, Enrico Bertino, Tatiana Boetti, Alessandra Coscia, R Bagna, Raffaela Mazzone |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Birth weight iron sulfate Physiology Infant Premature Diseases Drug Administration Schedule Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Reticulocyte 030225 pediatrics medicine Humans Ferrous Compounds 030212 general & internal medicine Erythropoietin Retrospective Studies bisglycinate chelate Anemia Iron-Deficiency treatment business.industry Iron deficiency Infant Newborn Gestational age medicine.disease haemoglobin Bioavailability Preterm newborn anaemia Iron sulfate Treatment Outcome medicine.anatomical_structure chemistry Pediatrics Perinatology and Child Health Hematinics Erythropoiesis Drug Therapy Combination Female business Infant Premature medicine.drug |
| Zdroj: | Current Pediatric Reviews |
| ISSN: | 1573-3963 |
| DOI: | 10.2174/1573396314666180124101059 |
| Popis: | Background: Strategies to prevent anaemia in preterm infants include drawing fewer blood samples, the use of recombinant human erythropoietin and iron supplementation. Although iron sulfate is the most commonly used pharmaceutical formulation for iron supplementation, there are few studies comparing different iron salts in infants. Objective: This is a study of retrospective data comparison of two groups of preterm infants receiving erythropoietin to evaluate the efficacy of iron bisglycinate chelate to iron sulfate. Subjects and Methods: Three-hundred infants of gestational age ≤32 weeks were enrolled: 225 were supplemented with iron sulfate (3 mg/kg/day) and 75 were supplemented with iron bisglycinate che-late (0.75 mg/kg/day). The effect on erythropoiesis was assessed with a general linear model that es-timates the response variables (values for Haemoglobin, Haematocrit, absolute values and percentage Reticulocytes, Reticulocyte Haemoglobin content) based on treatment, time, birth weight, and gesta-tional age. Results: Supplementation with iron bisglycinate chelate at a dose of 0.75 mg/kg/day demonstrated an efficacy comparable to iron sulfate at a dose of 3 mg/kg/day in both populations of preterm infants. The two cohorts had similar erythropoietic response, without significant differences. Conclusions: The higher bioavailability of iron bisglycinate chelate resulted in a lower load of ele-mental iron, a quarter of the dose, and achieved equivalent efficacy compared to iron sulfate. Iron bis-glycinate chelate may appear to be an alternative to iron sulfate in the prevention and treatment of pre-term newborn anaemia |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|